XML 79 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Segment Information
12 Months Ended
Dec. 31, 2019
Business Segment Information  
Business Segment Information

Note 13.

Business Segment Information

The Company has one business activity: the development and commercialization of therapies designed to treat glaucoma, corneal disorders and retinal diseases, and operates as one operating segment. The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company’s revenues disaggregated by revenue and product category are included in Note 8, Revenue from Contracts with Customers. The Company’s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its consolidated operating results for the purpose of allocating resources and evaluating financial performance.

Property and equipment, net

Depreciation and amortization

Capital expenditures

 

As of December 31,

Year ended December 31,

Year ended December 31,

 

2019

2018

2017

2019

2018

2017

2019

2018

2017

 

    

    

    

United States

    

$

21,932

$

19,040

    

$

11,677

    

$

6,273

$

6,234

    

$

5,406

    

$

4,681

$

10,288

    

$

6,051

International

124

 

113

 

117

33

 

30

 

76

44

 

27

 

221

Total

 

$

22,056

$

19,153

$

11,794

 

$

6,306

$

6,264

$

5,482

 

$

4,725

$

10,315

$

6,272